Lifeloc Reports Third Quarter 2026 Results
Key Highlights
- ➤Q3 revenue $2.522 million, up 12% year over year
- ➤Q3 net loss narrowed to $85 thousand, or $0.03 per diluted share
- ➤Q3 gross margin rose to 43% from 40% year over year
- ➤SpinDetect limited commercial launch delayed to Q4 2027
- ➤Nine-month operating cash flow turned positive at $14,618
Expert Statements
Wayne Willkomm, President and CEO of Lifeloc Technologies
“We are raising the priority of our alcohol testing research and development projects that can have a quick, positive impact on cash flow. While we had deferred some core business opportunities, transformational AI tools have reduced the cost and timeline for hardware and firmware upgrades, raising the return on investment for these projects,”
Wayne Willkomm, President and CEO of Lifeloc Technologies
“Using advances in our core products to fund the big growth opportunity of the SpinDetect™ Centrifugal Drug Analyzer is consistent with our desire to fund from operations as best as we can.”
WHEAT RIDGE, CO / ACCESS Newswire / November 16, 2026 / Lifeloc Technologies, Inc. (OTCID:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended September 30, 2026.
Lifeloc posted quarterly net revenue of $2.522 million in the third quarter of 2026, resulting in a quarterly net loss of $(85) thousand, or $(0.03) per diluted share. These results compare to net revenue of $2.257 million and quarterly net loss of $(263) thousand, or $(0.10) per diluted share in the third quarter of 2025. Revenue for the quarter grew 12% versus the third quarter last year. For the first nine months of 2026, net revenue was $7.261 million and net loss was $(372) thousand, or $(0.14) per diluted share, compared with net revenue of $6.754 million and net loss of $(950) thousand, or $(0.35) per diluted share, for the same period in 2025. Total gross margin in the third quarter rose to 43% versus 40% for the same quarter last year. For the first nine months of 2026, gross margin was 44% versus 41% for the same period last year, with price increases and a favorable product mix contributing to the higher margins. The research and development investment for the quarter remained high at $506 thousand, primarily for SpinDetect™ analyzer development, resulting in the current period loss.
Get started
Create a free account to read the full story.
